Results 111 to 120 of about 2,377 (150)

Immune reconstitution and tolerance-inducing therapies as promising therapeutic approaches in multiple sclerosis. [PDF]

Neurol Sci
Maal AB, Arki MK, Nabavi SM, Rezaei-Tavirani M, Rismani E, Vosough M, Azizi G, Hossein-Khannazer N.   +7 more
europepmc   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta-Analysis of Randomized Controlled Trials. [PDF]

Ann Clin Transl Neurol
Shahzad F, Rasheed T, Siddiqui MR, Hamid H, Khalid MB, Shabbir H, Shami B, Abdullah, Ahmed SI.   +8 more
europepmc   +1 more source

Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data. [PDF]

Pharmacol Rep
Balzano N, Di Napoli R, Fraenza F, Di Giulio Cesare D, Moreggia O, Cardillo M, Scavone C, Maniscalco GT, Capuano A, Sportiello L.   +9 more
europepmc   +1 more source

Personalized therapy in multiple sclerosis: an Italian Delphi consensus. [PDF]

J Neurol
Gasperini C, Centonze D, Conte A, Gallo P, Lugaresi A, Patti F, Trojano M, Amato MP, Filippi M.   +8 more
europepmc   +1 more source

Discovery of Sphingosine-1-Phosphate Receptor Modulators as Potential CHI3L1 Inhibitors by Ligand-Based Virtual Screening and Molecular Dynamics Simulations. [PDF]

ACS Omega
Aledavood E, Gil C, Comabella M, Martinez A.   +3 more
europepmc   +1 more source

Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders. [PDF]

Front Pharmacol
Chen S, Wu L, Lang B, Zhao G, Zhang W.
europepmc   +1 more source

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance. [PDF]

Mult Scler
Mullan G, Ford HL, Blackall P, Bongol D, Bonham N, Brex P, Hoyle N, Murray K, Nelson-Piercy C, Pearson OR, Rog D, Prinja P, Dobson R.   +12 more
europepmc   +1 more source

Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR). [PDF]

J Neurol
Monschein T, Untersteiner H, Ponleitner M, Krajnc N, Zrzavy T, Bsteh G, Rommer P, Kornek B, Enzinger C, Di Pauli F, Kraus J, Guger M, Leutmezer F, Berger T, Austrian MS Treatment Registry (AMSTR).   +14 more
europepmc   +1 more source

Personalized Treatment Response in Progressive MS: Can the Patient's Profile Influence the Outcome? [PDF]

Brain Behav
Bovis F, Kappos L, Arnould S, Karlsson G, Sormani MP.   +4 more
europepmc   +1 more source

Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia. [PDF]

Front Public Health
Al-Jedai A, Almudaiheem H, Al-Suweidan F, Jumah MA, Al-Thobaiti A, Alzureiqan F, Abu Ras W, Al-Dosari FM, Malik YA, Dhopte P, Ojeil R.   +10 more
europepmc   +1 more source